Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

Oragenics Stock Performance

NYSE:OGEN opened at $0.28 on Wednesday. The company has a market capitalization of $3.42 million, a P/E ratio of -0.04 and a beta of 0.49. The stock’s 50 day moving average price is $0.37 and its 200 day moving average price is $1.02. Oragenics has a 52 week low of $0.25 and a 52 week high of $7.74.

Hedge Funds Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC acquired a new stake in shares of Oragenics, Inc. (NYSE:OGEN) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.